Image de couverture de livre

Budget impact of a set-dose combination of efavirenz-emtricitabine-tenofovir in the treatment of patients infected with HIV-1

Fuente: Redalyc

Enregistré dans:

Détails bibliographiques
Auteur principal:	Itziar Oyagüez
Format:	Artículo científico
Langue:	en
Publié:	Sociedad Española de Farmacia Hospitalaria 2009
Sujets:	Medicina HIV Efavirenz Tenofovir Emtricitabine Budgetary impact
Accès en ligne:	Acceder al recurso
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Análisis del cambio en la adherencia y eficiencia del tratamiento antirretroviral con el uso de efavirenz-emtricitabina-tenofovir en dosis única diaria
par: S.E. García Ramos
Publié: (2012)

CYP2B6 516 G>T polymorphism and side effects of the central nervous system in HIV-positive individuals under Efavirenz treatment: Study of a sample from southern Brazi
par: TALISE E. MÜLLER
Publié: (2017)

Economic evaluation and budgetary burden of mepolizumab in severe refractory eosinophilic asthma
par: Leticia García-Mochón
Publié: (2019)

Simplification of HAART therapy on ambulatory HIV patients in Malaysia: a randomized controlled trial
par: Tineshwaran VELVANATHAN
Publié: (2016)

Análisis de las causas y factores predictivos de discontinuación del tratamiento con tenofovir en pacientes VIH pretratados
par: R. Morillo Verdugo
Publié: (2007)

HEPATITIS B Y C EN PERSONAS CON VIH DEL INSTITUTO PARA EL DESARROLLO HUMANO
par: Jhemel Garay Quiroga
Publié: (2021)

Effectiveness, safety, and patient‐reported outcomes of emtricitabine/tenofovir alafenamide‐based regimens for the treatment of HIV‐1 infection: Final 24‐month results from the prospective German TAFNES cohort study
par: Christoph Stephan, et autres
Publié: (2024)

Bictegravir/emtricitabine/tenofovir alafenamide in adults with HIV‐1 and end‐stage kidney disease on chronic haemodialysis
par: Joseph J. Eron, et autres
Publié: (2024)

Real‐world efficacy of bictegravir/emtricitabine/tenofovir alafenamide regimen in patients infected with HIV‐1 sub‐subtype A6 harbouring the L74I mutation
par: Elena Orlova‐Morozova, et autres
Publié: (2025)

Authors' Reply to Letter to the Editor Regarding ‘Effectiveness, safety, and patient‐reported outcomes of emtricitabine/tenofovir alafenamide‐based regimens for the treatment of HIV‐1 infection: Final 24‐month results from the prospective German TAFNES cohort study’
par: Christoph Stephan, et autres
Publié: (2025)

Influence of the Diagnostic and Interactive Use of the Budget on Managerial Performance Mediated by Organizational Commitment
par: Itzhak David Simão Kaveski
Publié: (2021)

Antecedents of Commitment to Budgetary Goals
par: Daniele Cristina Bernd
Publié: (2022)

The relationship between cost management knowledge and budgetary participation with managers’ performance
par: Alexandre Corrêa dos Santos
Publié: (2014)

Rapid start with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) as initial treatment in people with human immunodeficiency virus‐1 (HIV‐1): A systematic literature review of clinical and patient‐reported outcomes
par: Jade Ghosn, et autres
Publié: (2025)

The influence of the ethical climate on procedural justice and organizational commitment: the interaction of budgetary participation
par: Januário José Monteiro
Publié: (2021)

Effects of Budgetary Participation on Managerial Attitudes, Satisfaction, and Managerial Performance
par: Vinícius Costa da Silva Zonatto
Publié: (2020)

Blood pressure and metabolic outcomes after efavirenz‐ or dolutegravir‐based therapy started in acute HIV infection
par: Phillip Chan, et autres
Publié: (2025)

Efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide in Black and Hispanic/Latine adults with HIV‐1 initiating first‐line therapy: 5‐year follow‐up from two phase III studies
par: C. Martorell, et autres
Publié: (2025)

Accounting basis adjustments and deficit reliability: Evidence from southern European countries
par: Maria Antónia Jesus
Publié: (2016)

Enabling Knowledge Sharing within e-Government Back-Office Through Ontological Engineering
par: Graciela Brusa
Publié: (2007)

Cost-utility analysis of the fixed-dose combination of dolutegravir/abacavir/lamivudine as initial treatment of HIV+ patients in Spain
par: Santiago Moreno Guillén
Publié: (2017)

Effects of the management control system in unethical behaviors
par: Luciana Klein
Publié: (2019)

Voting behavior and budget stability
par: Cristina Vicente
Publié: (2013)

Metabolic effects of switching to Biktarvy (B/F/TAF) in patients with HIV‐1 treated with antiretroviral regimens that do not include tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide (TAF): The Metabic study
par: C. Busca‐Arenzana, et autres
Publié: (2024)

Zidovudine/Lamivudine vs. Abacavir/Lamivudine vs. Tenofovir/Emtricitabine in fixed-dose combinations as initial treatment for HIV patients: a systematic review and network meta-analysis
par: Juan Carlos Alzate Angel
Publié: (2017)

Risk factors for neurocognitive impairment in HIV-infected patients and comparison of different screening tools
par: Elisa Moreira de Souza
Publié: (2016)

THE FACES OF VULNERABILITY - WOMEN, MOTHER, HIV POSITIVE: REFLECTIONS ON WOMEN HEALTH NURSING
par: Isabel Catarina Correia Braga
Publié: (2010)

Factors associated to the control of viral load in HIV positive patients
par: Leticia Ferraz Pamplona
Publié: (2021)

Intracellular tenofovir‐diphosphate concentrations in HIV pre‐exposure prophylaxis users who underwent bariatric surgery
par: Matthew W. McGarrity, et autres
Publié: (2025)

CD4+ T‐cell recovery in HIV/hepatitis C co‐infected patients following successful hepatitis C treatment
par: Patrick Ryscavage, et autres
Publié: (2024)

Assessment of weight gain in adult patients living with HIV receiving first‐line dolutegravir‐based or efavirenz‐based ART regimens in routine care clinics in Tshwane district, South Africa: An observational study
par: Shobna Sawry, et autres
Publié: (2024)

Delayed HIV treatment, barriers in access to care and mortality in tuberculosis/HIV co-infected patients in Cali, Colombia
par: Jorge A González-Duran
Publié: (2021)

Prevalence of intestinal parasites in a cohort of HIV- infected patients from Antioquia, Colombia
par: Jorge Botero-Garcés
Publié: (2021)

Hepatitis B reactivation in people living with HIV and isolated anti‐ HBc receiving tenofovir‐sparing dual antiretroviral therapy
par: M. D. M. Arcos‐Rueda, et autres
Publié: (2026)

Pretreatment HIV Drug-resistance Surveillance as a Tool for Monitoring and Control of the HIV/AIDS Epidemic in Cuba
par: Liuber Y. Machado-Zaldívar
Publié: (2021)

Conflict and Change in EU Budgetary Politics
par: Lindner, Johannes
Publié: (2025)

Characterization of treatment failure in HIV positive patients in the Colombian Caribbean region
par: Juan Manuel De La Hoz
Publié: (2014)

HIV-1 Antiretroviral Resistance in Cuba, 2009–2014
par: Yoan Alemán-Campos
Publié: (2018)

Frequent hepatitis B surface antigen ( HBsAg) clearance during tenofovir therapy in persons with HIV /hepatitis B virus coinfection
par: Charles Béguelin, et autres
Publié: (2025)

Cytomegalovirus infection among people living with HIV in Sweden: Case profiles, treatment strategies and patient outcomes at Karolinska University Hospital 2010–2020
par: Xinling Xu, et autres
Publié: (2024)